Ilan Shapira, MD
Hematology & Oncology · New York, NYNPI 1649253675
Payments from drug & device makers
Across 580 payments — averaging $936.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$140K
- E.r. Squibb & Sons, L.L.C.$86K
- Johnson & Johnson$83K
- Genentech USA, Inc.$63K
- Bristol Myers Squibb$59K
- Takeda Pharmaceuticals U.S.A., Inc.$34K
- plus $78K from 26 others
What the payments were for
- Consulting fees$22,7685%
- Speaking & faculty fees$394,31483%
- Travel & lodging$43,7259%
- Food & beverage$13,8323%
- Education$4110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 140 | $139,793 |
| E.r. Squibb & Sons, L.L.C. | 54 | $85,679 |
| Johnson & Johnson | 96 | $83,109 |
| Genentech USA, Inc. | 55 | $63,432 |
| Bristol Myers Squibb | 79 | $59,108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $34,001 |
| Astellas Pharma Global Development | 2 | $24,455 |
| Pfizer | 6 | $16,213 |
| Kyowa Kirin, Inc. | 10 | $8,134 |
| Rigel Pharmaceuticals, Inc. | 22 | $7,847 |
| AstraZeneca(2 entities) | 9 | $7,173 |
| Gilead(2 entities) | 7 | $5,306 |
| Stemline Therapeutics Inc. | 2 | $3,269 |
| Karyopharm Therapeutics Inc. | 6 | $2,936 |
| Beigene USA, Inc. | 1 | $525 |
| Beigene, Ltd. | 1 | $450 |
| AbbVie | 7 | $374 |
| Incyte Corporation | 3 | $300 |
| Novartis | 11 | $259 |
| Amgen | 5 | $213 |
| Seagen Inc. | 1 | $133 |
| Pharmacosmos Therapeutics Inc. | 1 | $125 |
| Aurobindo Pharma USA, Inc. | 23 | $115 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Sobi, Inc | 2 | $40 |
| GSK | 2 | $38 |
| Genmab U.S., Inc. | 1 | $25 |
| Morphosys, US Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $22 |
| Sanofi | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $22 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$543,221 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 101 | $1,711,148 |
| ImbruvicaIbrutinib | 68 | $1,090,024 |
| Lenalidomide | 59 | $781,469 |
| NinlaroIxazomib Citrate | 55 | $682,725 |
| BosulifBosutinib | 21 | $352,174 |
| BrukinsaZanubrutinib | 21 | $320,805 |
| JakafiRuxolitinib Phosphate | 16 | $277,430 |
| PomalystPomalidomide | 11 | $277,195 |
| PromactaEltrombopag Olamine | 30 | $267,038 |
| CalquenceAcalabrutinib Maleate | 14 | $205,228 |
| ProcritEpoetin Alfa | 36 | $124,234 |
| XareltoRivaroxaban | 54 | $38,290 |
| EliquisApixaban | 40 | $33,217 |
| RetacritEpoetin Alfa-Epbx | 30 | $24,846 |
| Imatinib Mesylate | 74 | $15,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $59,108 | $1,711,148101 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $139,793 | $1,090,02468 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $34,001 | $682,72555 claims |
| PfizerBosulif, Eliquis, Retacrit | $16,213 | $410,23791 claims |
| Beigene USA, Inc.Brukinsa | $525 | $320,80521 claims |
| Incyte CorporationJakafi | $300 | $277,43016 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $85,679 | $277,19511 claims |
| NovartisPromacta | $259 | $267,03830 claims |
| AstraZenecaCalquence | $7,173 | $205,22814 claims |
| Johnson & JohnsonProcrit, Xarelto | $83,109 | $162,52390 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in New York
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
- Joshua SabariNew York$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.